Osteopore Secures Distribution Rights for Injectable Regenerative Bone Filler in Southeast Asia
Osteopore Limited (ASX: OSX) has obtained non-exclusive distribution rights for its injectable regenerative bone filler from dsm-firmenich, a prominent global leader in nutrition, health, and beauty. The agreement covers Southeast Asia (SEA) and adds a valuable product to Osteopore’s growing orthopaedic portfolio. The injectable bone filler will provide a minimally invasive solution for treating various orthopaedic bone defects, particularly in irregular bone gaps common in trauma and reconstruction surgeries.
The market for bone grafts and orthobiologics in SEA is experiencing rapid growth, estimated to range from AUD 94.6 million to AUD 284 million, driven by increased healthcare spending and higher surgical capacities. This new distribution agreement reflects growing market confidence in Osteopore’s commercial strategy. The company will begin product registration in Singapore, followed by expansion to other SEA countries, from 2026 to 2028.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Osteopore Secures Distribution Rights for Injectable Regenerative Bone Filler in Southeast Asia
Osteopore Limited (ASX: OSX) has obtained non-exclusive distribution rights for its injectable regenerative bone filler from dsm-firmenich, a prominent global leader in nutrition, health, and beauty. The agreement covers Southeast Asia (SEA) and adds a valuable product to Osteopore’s growing orthopaedic portfolio. The injectable bone filler will provide a minimally invasive solution for treating various orthopaedic bone defects, particularly in irregular bone gaps common in trauma and reconstruction surgeries.
The market for bone grafts and orthobiologics in SEA is experiencing rapid growth, estimated to range from AUD 94.6 million to AUD 284 million, driven by increased healthcare spending and higher surgical capacities. This new distribution agreement reflects growing market confidence in Osteopore’s commercial strategy. The company will begin product registration in Singapore, followed by expansion to other SEA countries, from 2026 to 2028.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au